In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

被引：45

作者：

Chávez, M

Bernal, S

Valverde, A

Gutierrez, MJ

Quindós, G

Mazuelos, EM ^{[1
]}

机构：

[1] Hosp Univ Valme, Serv Microbiol Clin, E-41014 Seville, Spain

[2] Univ Basque Country, Fac Med & Odontol, Dept Inmunol Microbiol & Parasitol, E-48080 Bilbao, Spain

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1999年 / 44卷 / 05期

关键词：

D O I：

10.1093/jac/44.5.697

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In this report we compare the activity of two new antifungal agents, voriconazole (UK-109,496) and LY303366 with the activities of other antifungals including fluconazole, itraconazole, 5-fluorocytosine (5FC) and amphotericin B against 219 oral Candida spp. isolates from HIV-infected patients. We used the broth microdilution method following the guidelines of the NCCLS. The in-vitro activity of voriconazole (UK-109,496) (MIC90 0.12 mg/L) and LY303366 (CMI90 0.25 mg/L) against clinical isolates of Candida spp. was excellent and comparable with that of amphotericin B (MIC90 0.5 mg/L), and better than those of fluconazole (MIC90 greater than or equal to 64 mg/L), itraconazole (MIC90 4 mg/L) and 5FC (MIC90 1 mg/L).

引用

收藏

页码：697 / 700

页数：4

相关论文

共 10 条

[1] In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and fluconazole) against Candida species [J].

Barry, AL ;

Brown, SD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1948-1949

[2] Echinocandins and pneumocandins - a new antifungal class with a novel mode of action [J].

Denning, DW .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) :611-614

[3] In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202

[4] Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans [J].

Krishnarao, TV ;

Galgiani, JN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) :1957-1960

[5] In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. [J].

Marco, F ;

Pfaller, MA ;

Messer, S ;

Jones, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :161-163

[6] Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis [J].

Murphy, M ;

Bernard, EM ;

Ishimaru, T ;

Armstrong, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :696-698

[7]

National Committee for Clinical Laboratory Standards, 1997, REF METH BROTH DIL A

[8] In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection [J].

Ruhnke, M ;

SchmidtWesthausen, A ;

Trautmann, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :575-577

[9]

Schwartz S, 1997, BRIT J HAEMATOL, V97, P663, DOI 10.1046/j.1365-2141.1997.972911.x

[10] In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates [J].

Uzun, O ;

Kocagoz, S ;

Cetinkaya, Y ;

Arikan, S ;

Unal, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1156-1157